Literature DB >> 1797953

Efficacy of Andrographis paniculata, Nees for pharyngotonsillitis in adults.

V Thamlikitkul1, T Dechatiwongse, S Theerapong, C Chantrakul, P Boonroj, W Punkrut, W Ekpalakorn, N Boontaeng, S Taechaiya, S Petcharoen.   

Abstract

One hundred and fifty-two adult patients with pharyngotonsillitis were enrolled in the randomized double blind study to assess the efficacy of Andrographis paniculata. The patients were randomized to receive either paracetamol or 3 g/day of Andrographis paniculata or 6 g/day of Andrographis paniculata for 7 days. The baseline characteristics of the patients among the three groups were not different. The efficacy of paracetamol or high dose Andrographis paniculata was significantly more than that of low dose Andrographis paniculata at day 3 in terms of the relief of fever and sore throat. The clinical effects were not different at day 7. Minimal and self limiting side effects were found in about 20 per cent in each group.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797953

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  20 in total

1.  Synergistic effect of 14-alpha-lipoyl andrographolide and various antibiotics on the formation of biofilms and production of exopolysaccharide and pyocyanin by Pseudomonas aeruginosa.

Authors:  Xiangping Zeng; Xiangyang Liu; Jiang Bian; Gang Pei; Huanqin Dai; Steven W Polyak; Fuhang Song; Li Ma; Yuqiang Wang; Lixin Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

2.  Apoptosis inducing effect of andrographolide on TD-47 human breast cancer cell line.

Authors:  Harjotaruno Sukardiman; Aty Widyawaruyanti; Noor Cholies Zaini
Journal:  Afr J Tradit Complement Altern Med       Date:  2007-02-16

Review 3.  Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.

Authors:  S F Yanuck; J Pizzorno; H Messier; K N Fitzgerald
Journal:  Integr Med (Encinitas)       Date:  2020

Review 4.  Drug-Herb Interactions in the Elderly Patient with IBD: a Growing Concern.

Authors:  Haider Rahman; Marina Kim; Galen Leung; Jesse A Green; Seymour Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

5.  Open label clinical trial to study adverse effects and tolerance to dry powder of the aerial part of andrographis paniculata in patients type 2 with diabetes mellitus.

Authors:  Renu Agarwal; Siti Amrah Sulaiman; Mafauzy Mohamed
Journal:  Malays J Med Sci       Date:  2005-01

Review 6.  Nain-e Havandi Andrographis paniculata present yesterday, absent today: a plenary review on underutilized herb of Iran's pharmaceutical plants.

Authors:  Alireza Valdiani; Mihdzar Abdul Kadir; Soon Guan Tan; Daryush Talei; Mohd Puad Abdullah; Sonia Nikzad
Journal:  Mol Biol Rep       Date:  2011-12-24       Impact factor: 2.316

7.  Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles.

Authors:  Bothiraja Chellampillai; Atmaram Pandurang Pawar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-12-30       Impact factor: 2.441

8.  Therapeutic Potential of Andrographolide Isolated from the Leaves of Andrographis paniculata Nees for Treating Lung Adenocarcinomas.

Authors:  Yu-Tang Tung; Hsiao-Ling Chen; Hsin-Chung Tsai; Shang-Hsun Yang; Yi-Chun Chang; Chuan-Mu Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-20       Impact factor: 2.629

9.  Experimental and Clinical Pharmacology of Andrographis paniculata and Its Major Bioactive Phytoconstituent Andrographolide.

Authors:  Thanasekaran Jayakumar; Cheng-Ying Hsieh; Jie-Jen Lee; Joen-Rong Sheu
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-24       Impact factor: 2.629

10.  Activity of andrographolide against chikungunya virus infection.

Authors:  Phitchayapak Wintachai; Parveen Kaur; Regina Ching Hua Lee; Suwipa Ramphan; Atichat Kuadkitkan; Nitwara Wikan; Sukathida Ubol; Sittiruk Roytrakul; Justin Jang Hann Chu; Duncan R Smith
Journal:  Sci Rep       Date:  2015-09-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.